Key statistics dashboard for None (HSDT). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Solana Co. is a medical device firm specializing in neurotechnology, dedicated to improving neurological wellness. The company's strategy involves developing, licensing, and acquiring innovative, non-invasive platform technologies. These technologies are designed to enhance the brain's intrinsic capacity for self-healing and mitigate the effects of neurological diseases or trauma.
Stock Data
| Price | $2.30 |
| Market Cap | $134M |
| Beta | 0.91 |
Valuation Multiples
| P/E Ratio | -0.07 |
| Price / Book | 1.06 |
| P/S | 10.83 |
| P/FCF | -4.85 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 95.53% |
| EBIT Margin | -1123.94% |
| EBITDA Margin | -1118.45% |
| Operating Margin | -200.47% |
| Net Margin | -1302.78% |
Financial Health
| Current Ratio | 13.31 |
| Quick Ratio | 13.31 |
| Cash Ratio | 1.69 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Interest Coverage | -355.90 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 11.60 |
Per-Share Data
| Revenue per share | 0.15 |
| Book Value per share | 2.12 |
| Cash per share | 0.05 |
| FCF per share | -0.34 |
| Tangible Book Value per share | 2.12 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 4 |
| Avg rating (1-5) | 0.50 |